- Home
- CDTX vs XENE Comparison
CDTX vs XENE Comparison
Compare CDTX & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDTX
- XENE
- Stock Information
- Founded
- CDTX 2012
- XENE 1996
- Country
- CDTX United States
- XENE Canada
- Employees
- CDTX N/A
- XENE N/A
- Industry
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- XENE Biotechnology: Pharmaceutical Preparations
- Sector
- CDTX Health Care
- XENE Health Care
- Exchange
- CDTX Nasdaq
- XENE Nasdaq
- Market Cap
- CDTX 2.8B
- XENE 2.9B
- IPO Year
- CDTX 2015
- XENE 2014
- Fundamental
- Price
- CDTX $109.03
- XENE $42.67
- Analyst Decision
- CDTX Strong Buy
- XENE Strong Buy
- Analyst Count
- CDTX 13
- XENE 10
- Target Price
- CDTX $118.50
- XENE $53.00
- AVG Volume (30 Days)
- CDTX 986.8K
- XENE 742.2K
- Earning Date
- CDTX 11-06-2025
- XENE 11-03-2025
- Dividend Yield
- CDTX N/A
- XENE N/A
- EPS Growth
- CDTX N/A
- XENE N/A
- EPS
- CDTX N/A
- XENE N/A
- Revenue
- CDTX N/A
- XENE $7,500,000.00
- Revenue This Year
- CDTX N/A
- XENE N/A
- Revenue Next Year
- CDTX N/A
- XENE $207.88
- P/E Ratio
- CDTX N/A
- XENE N/A
- Revenue Growth
- CDTX N/A
- XENE N/A
- 52 Week Low
- CDTX $12.54
- XENE $26.74
- 52 Week High
- CDTX $121.21
- XENE $46.00
- Technical
- Relative Strength Index (RSI)
- CDTX 57.26
- XENE 57.52
- Support Level
- CDTX $93.60
- XENE $40.79
- Resistance Level
- CDTX $107.00
- XENE $42.77
- Average True Range (ATR)
- CDTX 5.83
- XENE 1.45
- MACD
- CDTX -1.38
- XENE -0.09
- Stochastic Oscillator
- CDTX 39.96
- XENE 53.41
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.